Artisan
An AI BDR that automates outbound sales from lead sourcing to booking meetings.
Product memo
Artisan provides an autonomous AI BDR, Ava, for end-to-end outbound automation. It handles lead sourcing, multi-channel personalization, objection handling, and meeting booking. This approach offers predictable pipeline growth, targeting sales teams burdened by the complexity and cost of traditional outbound processes.
- For who
- Fast-growing B2B companies and sales teams
- Solves what
- Automating outbound sales with an AI BDR for lead generation, outreach, and meeting booking.
- Autonomous AI BDR
- Multi-channel personalized outreach
- Automated lead qualification and booking
Market demand
Artisan keyword demand
5 keywords
SimilarWeb keyword snapshot · directional estimate.
Operator & company
Operators
2 people
Maker · Source-backed
Maker · Source-backed
Company
- Team
VC / larger team
- HQ
United States
Operating model
- Business model
Hybrid
- Platform
Web app
- Audience
Sales
Builder strategy
- Strategy Type
- Niche Specialist
- Stage
- Vc Growth
- Effort
- Small Team
About Artisan Expand
Artisan offers an AI BDR named Ava, designed to automate the entire outbound sales process for fast-growing B2B companies. This includes lead sourcing and enrichment, multi-channel outreach, and automated meeting booking.
The platform aims to provide predictable pipeline growth by replacing the manual effort of traditional BDRs with an autonomous AI. This helps sales teams manage the high costs and complexities often associated with human-led outbound efforts, offering a scalable alternative for consistent lead generation.
In their own words
Hire Ava
The autonomous AI BDR
Ava outperforms your best rep, runs without oversight, and scales your entire outbound motion end to end.
Competitive context
4 peers · Same primary niche.
Commercial cues
- Model
- hybrid
- Free tier
- Yes
- Trial
- 30 days
Pricing strategy
- • A free tier lets users test lead enrichment and basic outbound.
- • Credit-based pricing scales directly with outbound activity volume.
- • 30-day trial lowers adoption risk.